NewsRoom Articles - BioMedWire (BMW)

WednesdayFeb 18, 2026 9:45 am

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and the difficulty of scaling advanced treatment capacity fast enough to meet demand. A Two-Track Strategy: Sensitizing Tumors, Modernizing Delivery LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is pursuing a model that tries to improve cancer outcomes from two directions at once. On the therapeutic side, the company’s lead asset is LB-100, a clinical-stage compound designed to inhibit protein phosphatase 2A (“PP2A”), a biological target involved in cellular stress response and DNA repair pathways. LIXTE’s stated strategy is not to replace standard…

TuesdayFeb 17, 2026 9:00 am

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system (“CNS”) indications, into focus as strategic assets aligned with current M&A priorities. The company just…

FridayFeb 13, 2026 10:00 am

Groundbreaking Study Uncovers Why Breast Cancer Metastasizes to the Brain

A groundbreaking study led by a pair of researchers from Israel and involving research teams in several countries has discovered why some forms of breast cancer metastasize into the brain and become deadly. Their findings could open new doors in the management of breast cancer and address the needs of patients who are at a higher risk of developing metastases in the brain. The study, whose findings appeared in the Nature Genetics journal, was led by Professor Uri Ben-David and his colleague Professor Ronit Satchi-Fainaro, both working at Gray Faculty of Medical & Health Sciences in Tel Aviv, Israel. Other researchers who were involved in the study were…

FridayFeb 13, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit These two announcements paint a picture of a company advancing on multiple fronts LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore…

FridayFeb 13, 2026 9:00 am

Earth Science Tech Inc. (ETST) Driving Growth Through Strategic Healthcare Integration

ETST operates as an active strategic holding company, acquiring and optimizing businesses through direct management and governance. The company’s core operations focus on the health and wellness sector via a vertically integrated portfolio. ETST’s mission centers on building durable shareholder value through regulatory discipline, operational control, and scalable growth platforms. A Hands-On Approach to Portfolio Management Earth Science Tech (OTC: ETST) is redefining the traditional holding company model by building a diversified portfolio designed for long-term sustainability. Unlike passive investment vehicles, ETST takes an active role in its subsidiaries, utilizing hands-on management and disciplined execution to enhance performance across the board.…

ThursdayFeb 12, 2026 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year

HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum. HeartBeam’s technology is aligned with evolving regulatory and clinical priorities. In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report. HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through…

ThursdayFeb 12, 2026 10:00 am

Early Symptoms of Lung Cancer You Could Be Ignoring

Many times, a diagnosis of lung cancer comes late because the early symptoms may be dismissed since they are so subtle and can be mistaken for other illnesses. However, as with any other cancer, catching lung cancer early offers the best chance of getting better treatment outcomes. We explore some of those early warning signs that you may be downplaying. When you develop a cough that persists for several weeks, don’t be too quick to dismiss it as just an ordinary cough. Many times, that cough could be the result of an infection, an allergy, or pollution or be dismissed as “smoker’s cough.” However, it could also be pointing to something more serious, like lung cancer,…

TuesdayFeb 10, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology

One of the key advantages of photodynamic therapy is its selectivity. Soligenix is advancing HyBryte(TM), or SGX301, designed for the treatment of cutaneous T-cell lymphoma. The company has achieved an important safety milestone in its confirmatory phase 3 clinical trial of HyBryte for CTCL treatment. From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin diseases using targeted photodynamic…

TuesdayFeb 10, 2026 10:00 am

Why the Cost of Health Care in the US is Soaring

While people have been quick to blame health insurers for the skyrocketing cost of health care in the U.S., the reality of the situation is more nuanced, and other factors have played a much bigger role in driving up costs. We explore some of those less-reported drivers of the high cost of health care in the country. For example, the law caps the rates levied by medical facilities when treating patients on Medicare. However, private insurers aren’t constrained by these laws as they negotiate their rates directly with the health care facilities serving their clients. In order to be more appealing to patients on private insurance policies, hospitals are racing to upgrade…

MondayFeb 09, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over technologies that are currently available for treating tumors with proton therapy The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers. Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

Groundbreaking Study Uncovers Why Breast Cancer Metastasizes to the Brain

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

Earth Science Tech Inc. (ETST) Driving Growth Through Strategic Healthcare Integration

HeartBeam Inc. (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year

Early Symptoms of Lung Cancer You Could Be Ignoring

Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology

Why the Cost of Health Care in the US is Soaring

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search